Assessment of survival and quality of life with coloretal cancer
Keywords:
Câncer colorretal, FOLFOX, FOLFIRI, bevacizumabe, qualidade de vida, sobrevida.Abstract
Colorrectal cancer (CCR) is the third cause of cancer around the world and its treatment is done by the use of antineoplastic drugs alone or combined to monoclonal antibodies. However, the effects of these combinations on the patient’s quality of life are, until now, poorly understood.
Objectives: Verify the influence of fluorouracil, leucovorin, oxaliplatin (FOLFOX) and irinotecan (FOLFIRI) treatments alone or when associated to bevacizumab monoclonal antibody related to CCR patient’s quality of life.
Methods: 15 patients with CCR were interviewed and divided in groups based on the treatments received, and its quality of life was evaluated through the questionnaires EORTC-QLQ-C30/version 3.0 and EORTC-QLQ-CR38.
Results: We notice that patients without metastasis presented a better quality of life when compared to patients with metastasis. Indeed, we observed a tendency to a better quality of life in the group of patients with metastasis when treated with FOLFOX associated to bevacizumab when compared to the group that used FOLFOX alone. Patients with metastasis, when treated with FOLFIRI associated to bevacizumab, although presented a better function scale, also showed more symptoms when compared to patients with metastasis treated only with FOLFIRI. According to literature reports, the association of bevacizumab with conventional therapy demonstrated a tendency to promote an increase in overall survival and a reduction in the disease progression in an average of 5-6 months.
Conclusion: The association of bevacizumab with conventional therapy demonstrated a tendency to increase patient’s quality of life, characterized by an increase in its overall survival and progression-free survival.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
